Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.

× No keyword cloud information.

15 in total

1. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase.

Authors: G Bartholini; M Da Prada; A Pletscher
Journal: J Pharm Pharmacol Date: 1968-03 Impact factor: 3.765

2. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.

Authors: F K Goodwin; H K Brodie; D L Murphy; W E Bunney
Journal: Lancet Date: 1970-05-02 Impact factor: 79.321

3. The effect of L-DOPA treatment on brain serotonin metabolism in depressed patients.

Authors: F K Goodwin; D L Dunner; E S Gershon
Journal: Life Sci I Date: 1971-07-01

4. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.

Authors: B Johansson; B E Roos
Journal: Eur J Clin Pharmacol Date: 1971-09 Impact factor: 2.953

5. The effect of L-dopa on monoamine metabolites in Parkinson's disease.

Authors: M H van Woert; M B Bowers
Journal: Experientia Date: 1970

6. Critical analysis of the disability in Parkinson's disease.

Authors: D D Webster
Journal: Mod Treat Date: 1968-03

7. Brain capillaries as a source of homovanillic acid in cerebrospinal fluid.

Authors: G Bartholini; R Tissot; A Pletscher
Journal: Brain Res Date: 1971-03-19 Impact factor: 3.252

8. A spectrofluorometric method for the simultaneous determination of 2-(5-hydroxyindol-3-yl) ethylamine (serotonin) and 5-hydroxyindol-3-yl-acetic acid in the brain.

Authors: E Giacalone; L Valzelli
Journal: Pharmacology Date: 1969 Impact factor: 2.547

Review 9. Dopamine (3-hydroxytyramine) and brain function.

Authors: O Hornykiewicz
Journal: Pharmacol Rev Date: 1966-06 Impact factor: 25.468

10. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors: H EHRINGER; O HORNYKIEWICZ
Journal: Klin Wochenschr Date: 1960-12-15

2 in total

1. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors: G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal: Eur J Clin Pharmacol Date: 1977-04-20 Impact factor: 2.953

Review 2. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors: Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal: Front Cell Neurosci Date: 2014-11-11 Impact factor: 5.505

2 in total